4th OPTIMIZE – presentations

 
Who Should We Treat? What is the “Point-of-No-Return”?
Dr. Norah Terrault, MD, MPH
University of California, San Francisco, USA
 
Is Treatment Cost-effective?
Dr. Kosh Agarwal, MD
Kings College Hospital, United Kingdom
 
Treatment Experienced GT3 patient with Cirrhosis
Dr. Geoffrey McCaughan, MD, PhD
University of Sydney, Royal Prince Alfred Hospital, Australia
 
What Are the Treatment Options?
Dr. Xavier Forns, MD
Hospital Clinic Barcelona, Spain
 
When to Treat HCV in a Waiting List Patient?
Dr. Stefano Fagiuoli, MD
Azienda Ospedaliera Papa Giovanni XXIII, Italy
 
Achieving SVR in CTP C – MELD Purgatory
Dr. Christophe Duvoux, MD
Hôpital Henri Mondor, France
 
Use of HCV+ Donor Grafts
Dr. Didier Samuel, MD, PhD
Hôpital Paul Brousse, France
 
What Are the Treatment Options?
Dr. Maria Londoño, MD
Hospital Clinic Barcelona, Spain
 
Obstacles to Treatment: Renal Disease, Ribavirin, DDIs
Dr. Michael Charlton, MD
Intermountain Medical Center, USA
 
Post-LT Renal Failure and HCV Rx
Dr. Peter Ferenci, MD
University of Vienna, Austria
 
Management of DAA Failures
Dr. Gregory T. Everson, MD
University of Colorado, USA